Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The co-administration of SGLT2 inhibitor and GLP-1 receptor agonist would be safe and
effective on glycemic control in subjects with type 2 diabetes mellitus and MAFLD better than
empagliflozin or dulaglutide alone.
The SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on fatty liver
disease in subjects with type 2 diabetes mellitus and MAFLD.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Bundang Hospital
Treatments:
Dulaglutide Empagliflozin Immunoglobulin Fc Fragments